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Linear ubiquitination is a key posttranslational modiﬁcation that regulates immune signaling and cell death pathways, notably
tumor necrosis factor receptor 1 (TNFR1) signaling. The only known enzyme complex capable of forming linear ubiquitin
chains under native conditions to date is the linear ubiquitin chain assembly complex, of which the catalytic core component is
heme-oxidized iron regulatory protein 2 ubiquitin ligase-1–interacting protein (HOIP). To understand the underlying mecha-
nisms of maintenance of liver homeostasis and the role of linear ubiquitination speciﬁcally in liver parenchymal cells, we investi-
gated the physiological role of HOIP in the liver parenchyma. To do so, we created mice harboring liver parenchymal cell–
speciﬁc deletion of HOIP (HoipDhep mice) by crossing Hoip-ﬂoxed mice with albumin–Cre mice. HOIP deﬁciency in liver
parenchymal cells triggered tumorigenesis at 18 months of age preceded by spontaneous hepatocyte apoptosis and liver inﬂam-
mation within the ﬁrst month of life. In line with the emergence of inﬂammation,HoipDhep mice displayed enhanced liver regen-
eration and DNA damage. In addition, consistent with increased apoptosis, HOIP-deﬁcient hepatocytes showed enhanced
caspase activation and endogenous formation of a death-inducing signaling complex which activated caspase-8. Unexpectedly,
exacerbated caspase activation and apoptosis were not dependent on TNFR1, whereas ensuing liver inﬂammation and tumori-
genesis were promoted by TNFR1 signaling. Conclusion: The linear ubiquitin chain assembly complex serves as a previously
undescribed tumor suppressor in the liver, restraining TNFR1-independent apoptosis in hepatocytes which, in its absence, is
causative of TNFR1-mediated inﬂammation, resulting in hepatocarcinogenesis. (HEPATOLOGY 2017;65:1963-1978).
Chronic hepatitis is the leading cause of livercancer, which is one of the most lethal cancersworldwide.(1,2) Infection with hepatotropic viruses and excessive alcohol intake are among the majorcauses of hepatitis. As tumor necrosis factor (TNF) is amajor proinﬂammatory cytokine which can induce liver
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ligand 3; CD, cluster of differentiation; CD95L, CD95 ligand; c-FLIPL, cellular FLICE-like inhibitory protein long isoform; CHX, cycloheximide;
cpdm, chronic proliferative dermatitis mice; Cre, cyclization recombination; Cxcl1, chemokine (C-X-C motif) ligand 1; DD, death domain; ERK, extra-
cellular signal-regulated kinase; FADD, Fas-associated with DD; HCC, hepatocellular carcinoma; HOIL-1, heme-oxidized iron regulatory protein 2
ubiquitin ligase; HOIP, heme-oxidized iron regulatory protein 2 ubiquitin ligase–interacting protein; IKK, IjB kinase; JNK, c-Jun N-terminal kinase;
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cell apoptosis,(3) TNF blockade has been tested in
patients suffering from hepatic complications. Indeed,
therapies targeting TNF have shown promising results
in improving nonalcoholic steatohepatitis in
humans.(4,5) However, by contrast, anti-TNF therapy
has not been successful in ameliorating alcoholic hepati-
tis(6) and, unexpectedly, can even trigger reactivation of
hepatitis B virus infection by preventing viral clear-
ance.(7) Thus, dissection of the TNF/TNF receptor 1
(TNFR1) system in distinct etiologies and cell types is
crucial to improve the strategy for intervention of liver
diseases.
Several studies have revealed a key role for TNFR1
signaling in liver inﬂammation and cancer in mouse
models. For instance, liver parenchymal cell (LPC)–spe-
ciﬁc IjB kinase (IKK) b–deﬁcient mice are more sus-
ceptible to diethylnitrosamine-induced cell death and
carcinogenesis.(8) Follow-up studies employing LPC-
speciﬁc nuclear factor-jB (NF-jB) essential modulator
(NEMO) and transforming growth factor b–activated
kinase 1 (TAK1) knockout (KO) mice indicated that
indeed optimal regulation of TNFR1 signaling is crucial
to maintain liver homeostasis and to protect from
inﬂammation and cancer.(9,10) Importantly, in addition
to the regulation of NF-jB, aberrant activation of cell
death machineries triggered by deregulated TNFR1 sig-
naling can evoke severe liver pathology. For instance,
hepatocyte apoptosis and hepatocarcinogenesis due to
LPC-speciﬁc TAK1 deﬁciency are mediated by
caspase-8 in those cells, while cholestasis was induced
by the necroptosis inducer receptor–interacting protein
kinase (RIPK3).(11) Furthermore, transforming growth
factor b–activated kinase 1 and the IKKa–IKKb–
NEMO complex have been shown to suppress cell
death signaling independently of their role in activating
NF-jB in hepatocytes and other cell types.(12,13) Thus,
deregulated cell death and/or NF-jB signaling in hepa-
tocytes can result in liver inﬂammation and
carcinogenesis.
Ubiquitination is a crucial posttranslational modiﬁ-
cation mediated by ubiquitin ligases to deﬁne and ﬁne-
tune the biological function of substrate proteins.(14)
Notably, the linear ubiquitin chain assembly complex
(LUBAC), the only known ubiquitin ligase complex
capable of forming linear diubiquitin linkages de
novo,(15) has pivotal immunoregulatory and anti–cell
death functions in a wide range of innate and adaptive
immune signaling pathways, including those triggered
by TNFR1.(16-18) LUBAC is comprised of heme-
oxidized iron regulatory protein 2 ubiquitin ligase–
interacting protein (HOIP), heme-oxidized iron regu-
latory protein 2 ubiquitin ligase (HOIL-1), and
SHANK-associated RH domain interacting protein
(SHARPIN).(15,19) Deﬁciency in HOIP, the catalytic
LUBAC component, results in embryonic lethality at
mid-gestation due to TNFR1-mediated endothelial
cell death.(20) Indeed, HOIP-deﬁcient mouse embry-
onic ﬁbroblasts display a robust formation of the cell
death–inducing signaling platform complex II of
TNFR1 signaling, containing Fas-associated with
death domain (FADD), caspase-8, RIPK1, and
RIPK3, upon TNF stimulation.(20) SHARPIN-null
mice (chronic proliferative dermatitis mice or cpdm
mice), by contrast, develop TNFR1-dependent multi-
organ inﬂammation, including the liver, with TNFR1-
independent aberration in lymphoid tissues.(19,21,22)
Interestingly, abnormalities in cpdm mice are complete-
ly corrected by genetic ablation of RIPK3 and hetero-
zygosity of caspase-8 or epidermal ablation of
FADD.(21,23) These studies collectively corroborate a
central role of LUBAC in restraining aberrant activa-
tion of TNFR1-induced cell death machineries in
order to maintain tissue homeostasis.
Although cpdm mice exhibit liver inﬂammation, it
remains unknown which tissues and cell types con-
tribute to hepatitis. In addition, the physiological role
of LUBAC in LPCs remains unknown. Here, we
investigated the role of linear ubiquitination and
LUBAC in liver inﬂammation and carcinogenesis by
studying mice that lack HOIP, the central and cata-
lytically active component of LUBAC, speciﬁcally in
LPCs.
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Materials and Methods
ANIMALS
All animal studies were conducted according to an
appropriate license under the Animals (Scientiﬁc Proce-
dures) Act of 1986. HOIP-ﬂoxed (Hoipﬂox) mice were
created from the C57BL/6 embryonic stem cell clone
EPD0161_5_A05 from KOMP Repository (http://
www.komp.org) and generated by the Wellcome Trust
Sanger Institute (Hinxton, UK).(20) Hoipﬂox mice were
subsequently crossed to albumin promoter–driven Cre
recombinase (Alb-Cre) mice (B6.Cg-Tg[Alb-
cre]21Mgn/J) purchased from Jackson Laboratories (Bar
Harbor, ME) to delete HOIP in LPCs. TNFR1-
deﬁcient mice (B6.129-Tnfrsf1atm1Mak/J) and cluster
of differentiation 95 (CD95) death domain (DD)–ﬂoxed
mice (C57BL/6-Fastm1Cgn/J) were purchased from
Jackson Laboratories. Mice were maintained at Charles
River (Margate, UK) and UCL Biological Service Unit
(London, UK) under speciﬁc pathogen-free conditions
and a 12-hour dark/light cycle and fed ad libitum. Both
males and females were used in the experiments.
OTHER METHODS
For details of histology and immunohistochemistry,
immunoprecipitation, ﬂow cytometric analysis of liver
immune cells, isolation of mouse primary hepatocytes,
cell viability assay, western blotting, tissue RNA
extraction, quantitative RT-PCR, and RNA sequenc-
ing, see Supporting Information.
Results
HEPATOCYTE-SPECIFIC
DELETION OF HOIP LEADS
TO LIVER TUMORIGENESIS
To speciﬁcally investigate the role of linear ubiquitination
in the maintenance of liver homeostasis, we generated mice
with LPC-speciﬁc deletion of HOIP by crossing Hoipﬂox
mice(20) with Alb-Cremice.(24) Mice deﬁcient for HOIP in
the liver, referred to asHoipDhepmice, showed efﬁcient abla-
tion of HOIP protein in primary hepatocytes at 8-9 weeks
of age (Supporting Fig. S1A). The levels of the other two
LUBAC components, HOIL-1 and SHARPIN, were
mildly reduced by abrogation of HOIP, in line with previ-
ous reports on other tissues and cells.(19,20,25) TNFR
signaling complex pull-down analysis revealed that HOIP-
deﬁcient cells produced drastically reduced levels of linear
ubiquitination within the TNFR signaling complex (Sup-
porting Fig. S1B). The residual linear ubiquitination
observed in hepatocytes isolated fromHoipDhepmice is most
likely due to an incomplete penetrance of gene deletion by
Alb-Cre, which can be seen in substantially reduced yet
detectable levels of HOIP in these cells.
HoipDhep mice were as viable as Hoipﬂox littermate con-
trols at least up to 18 months (Supporting Fig. S1C).
However, at this stage the vast majority of HoipDhep mice
developed macroscopic lesions and nodules in the liver,
while age-matched littermate control mice did not show
any overt liver pathology (Fig. 1A, top panels). The size,
number, and severity of macroscopic lesions appearing in
HoipDhep livers were variable, with some mice developing
mild (small lesions; 5/13), moderate (multiple lesions and
nodules; 5/13), or severe (large nodules and cystic lesions;
3/13) pathology (Fig. 1A; Supporting Fig. S2A,B). His-
topathological analysis showed that more than half of the
HoipDhep animals displaying moderate or severe pathology
developed hepatocellular carcinoma (HCC) (5/8) and
that those which had not developed HCC displayed pre-
cancerous anisokaryosis or inﬂammatory foci (Fig. 1A,B).
The tumor nodules analyzed stained positively for gluta-
mine synthase and were negative for cytokeratin 19, indi-
cating that the tumors originated from the hepatocyte
and not the cholangiocyte lineage (Fig. 1C; Supporting
Fig. S2C). Of note, glutamine synthase staining showed
a diffuse pattern, which is often observed in human
HCC.(26) In addition,HoipDhep livers displayed focal lipid
accumulation, which was occasionally accompanied by
inﬂammation, indicating that HoipDhep mice developed
steatosis (Supporting Fig. S2D).
In order to further molecularly characterize the
tumors arising in HoipDhep mice, we used RNA
sequencing to compare the gene expression proﬁles of
nontumor tissue to tumor nodules from HoipDhep mice.
The expression proﬁles of all four nodular samples ana-
lyzed were clearly distinguished from those of non-
tumorous samples (Fig. 1D). The genes which were
up-regulated in the nodular samples were predomi-
nantly regulators of mitosis and cell cycle progression
(Fig. 1E). This expression signature observed in the
tumor samples from HoipDhep mice resembles that of
the subclass A and G1-G3 of human HCC described
by Thorgeirsson’s and Zucman-Rossi’s groups, respec-
tively, which are correlated with poor prognosis.(27,28)
Thus, HOIP deletion results in late formation of
hepatic tumor nodules with overexpressed cell cycle
regulatory genes.
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FIG. 1. HOIP deletion leads to spontaneous liver tumorigenesis. (A) Representative pictures of livers from Hoipﬂox and HoipDhep mice
at 18 months of age (upper panels). Black arrowheads indicate large nodules, and white arrowheads indicate cystic lesions. Bar graphs
indicate the incidence of macroscopic nodules (diameter >2 mm), maximal lesion size, lesion number, and the most advanced tumor
type in HoipDhep livers with macroscopic nodules (diameter >2 mm). Fisher’s exact test was employed for the statistical analysis of inci-
dence of macroscopic nodules. (B) Hematoxylin and eosin staining of Hoipﬂox liver and lesion areas (inﬂamed and HCC) in HoipDhep
livers. (C) Glutamine synthase and cytokeratin 19 staining of nontumoral and tumoral areas of the liver in HoipDhep mice. Arrowheads
indicate cytokeratin 19–positive bile ducts. (D) Clustering analysis of 714 differentially expressed genes (q value < 0.05) in the nodules
in HoipDhep livers compared to nontumor samples in these livers. (E) Upper schematics represent enriched neighborhood-based sets of
the top 182 differentially expressed genes in the tumor nodules (log2 [tumor/nontumor] >1.2) using ConsensusPathDB. The size of
circles corresponds to the number of related genes found in the analyzed gene set. More than ﬁve genes shared in the two nodes are
connected with a line (thicker line, 10 or more genes shared). Lower tables show enriched gene ontology–based sets of the 182 differ-
entially expressed genes. Abbreviations: CK19, cytokeratin 19; GO, gene ontology; GS, glutamine synthase; L, lesional area; NT, non-
tumor; T, tumor.
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INFLAMMATION ACCOMPANIED
BY DNA DAMAGE EMERGES
AT EARLY STAGES OF LIFE IN
HOIP-DEFICIENT LIVERS
Inﬂammation is often a crucial step in liver carcino-
genesis. In order to decipher whether deletion of
HOIP from hepatocytes triggered inﬂammation, we
studied HoipDhep livers within the ﬁrst months of life.
We ﬁrst tracked the number of leukocytes in the liver
by counting hepatic CD451 cells from Hoipﬂox and
HoipDhep animals from postnatal day 7 up to 8-9 weeks
of age. At postnatal days 7 and 15, leukocyte counts
were comparable between Hoipﬂox and HoipDhep livers
(Fig. 2A). Yet, at 4 weeks of age, leukocyte numbers
signiﬁcantly increased in HoipDhep livers compared to
control livers (Fig. 2A). In accord, elevated levels of
Tnf, chemokine (C-C motif) ligand 3 (Ccl3), and che-
mokine (C-X-C motif) ligand 1 (Cxcl1) were observed
at 4 weeks and notably at 2 weeks of age, when inﬂam-
mation was not detected in HoipDhep livers by leukocyte
count (Fig. 2B). However, the inﬂammation observed
at 4 weeks was transient as the difference in leukocyte
numbers between Hoipﬂox and HoipDhep became mar-
ginal at 8-9 weeks of age (Fig. 2A). Inﬁltration of mye-
loid cells was observed at the sites of inﬂammation in
HoipDhep livers at 4 weeks of age (Supporting Fig. S3).
To further investigate whether certain immune cell
compartments were particularly involved in the onset
of inﬂammation in HoipDhep livers at 4 weeks, we ana-
lyzed the various subpopulations of liver cells by ﬂow
cytometry. Monocytes/macrophages, granulocytes,
CD41 and CD81 T cells, and B cells were accumulat-
ed in HoipDhep livers compared to control livers (Fig.
2C). This result showed that immune cells from both
the myeloid and lymphoid compartments are recruited
to the inﬂamed HoipDhep livers and participate in
inﬂammatory responses, which coincides with
increased production of cytokines. Together, these
data indicate that deﬁciency of HOIP from liver
parenchyma elicits an acute immune response in the
ﬁrst 4 weeks of life, followed by a resolution phase
between weeks 4 and 9.
Upon liver damage, hepatocytes and liver cell pro-
genitors undergo compensatory proliferation to replen-
ish liver and maintain tissue integrity.(29) Indeed,
HOIP deletion resulted in initiation of liver regenera-
tion as a higher number of Ki-671 proliferating liver
cells in HoipDhep mice compared to littermate controls
was detected at 2-4 weeks (Fig. 2D). Additionally, an
inﬂammatory environment can lead to accumulation of
DNA damage and inﬂammation-associated carcino-
genesis.(30) Intriguingly, HoipDhep livers presented
increased cH2AX1 foci, which are used as a DNA
damage marker (Fig. 2E). Taken together, HOIP deﬁ-
ciency in LPCs results in transient liver inﬂammation
at early stages of life, and this inﬂammation is accom-
panied by a DNA damage response and regeneration
of hepatocytes.
HOIP DELETION IN THE LIVER
PARENCHYMA RESULTS IN LIVER
DAMAGE AND HEPATOCYTE
APOPTOSIS PRIOR TO
INFLAMMATION
To quantitatively evaluate the extent of liver damage
in HoipDhep mice, we determined serum alanine amino-
transferase (ALT) levels. In agreement with the leuko-
cyte counts, serum levels of ALT from HoipDhep mice
showed a moderate yet signiﬁcant surge at 2 weeks,
which peaked at 4 weeks and declined between 4 and
8 weeks of age (Fig. 3A). It is known that the Alb-Cre
mice express the Cre recombinase in cholangiocytes
(bile duct cells) in addition to hepatocytes.(9) Indeed,
values of the bile duct damage marker alkaline phos-
phatase were signiﬁcantly elevated in the sera of
HoipDhep mice and correlated well with the surge in
ALT values (Supporting Fig. S4A, left panel). A
minority of HoipDhep mice also displayed high levels of
serum bilirubin (>0.5 mg/dL), indicating that the ani-
mals suffered from cholestasis, which may contribute
to liver damage (Supporting Fig. S4A, right panel).
Collectively, these results show that HOIP deletion in
LPCs elicits liver damage and hepatocyte death and,
importantly, that both of these events predate the onset
of inﬂammation.
We next aimed to identify the event that resulted in
inﬂammation in HoipDhep livers at 4 weeks of age. To
do so, we performed a histological analysis of HoipDhep
mice from postnatal day 1 up to 8 weeks of age (Fig.
3B). While no aberration in HoipDhep livers was
observed at postnatal day 1, apoptotic bodies in
HoipDhep livers were detected at postnatal day 7, and
they became more prevalent at 2 weeks of age com-
pared to littermate controls. At 4 weeks of age, i.e., at
the peak of inﬂammation (Fig. 2A), we detected tissue
collapse in addition to apoptotic bodies and ductular
reactions (Fig. 3B). In line with the observation that
inﬂammation was ameliorated at 8 weeks of age (Fig.
2A), apoptotic bodies and ductular reactions were also
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FIG. 2. Inﬂammation accompanied by DNA damage emerges in HOIP-deleted livers. (A) Hepatic CD451 cell count per gram of
Hoipﬂox (open circles) and HoipDhep mice (closed circles) at the indicated ages. (B) Relative quantiﬁcation of the transcript levels of
Tnf, Ccl3, and (Cxcl1) in Hoipﬂox and HoipDhep livers (n 5 4 each). Levels of transcripts were normalized to those of Hoipﬂox livers.
(C) Liver cells from Hoipﬂox and HoipDhep mice at 4 weeks of age were stained, and the numbers of hepatic immune subpopulations
were quantiﬁed by ﬂow cytometry. (D) Ki-67 staining (red) of liver sections from Hoipﬂox and HoipDhep mice at 4 weeks of age. The
dot plot shows the quantiﬁcation of Ki-671 cells per optical area. (E) cH2AX staining (red) of liver sections from Hoipﬂox and
HoipDhep mice at 4 weeks of age. The dot plots show the quantiﬁcation of cH2AX1 cells per optical area. Unpaired two-tailed t test
was employed for statistical analysis. Abbreviations: Bc, B2201 cells; CD4 Tc, CD31 CD41 cells; CD8 Tc, CD31 CD81 cells; Gr,
Ly6G1 cells; Mo/MF, F4/801 cells; NK, CD32 NK1.11 natural killer cells; NKT, CD31 NK1.11 natural killer T cells.
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FIG. 3. HOIP deletion in the liver parenchyma results in increased apoptosis. (A) Levels of serum ALT in Hoipﬂox (open circles)
and HoipDhep mice (closed circles) at the indicated ages. (B) Hematoxylin and eosin staining of the livers of Hoipﬂox and HoipDhep mice
at the indicated ages. Black arrowheads indicate apoptotic bodies, and white arrowheads indicate areas showing the ductular reaction.
(C) Quantiﬁcation of CC31 and TUNEL1 cells per ﬁeld of Hoipﬂox and HoipDhep liver sections. (D) Lysates of primary hepatocytes
from Hoipﬂox and HoipDhep mice at 8-10 weeks of age were immunoblotted for CC8 and CC3. Unpaired two-tailed t test was
employed for statistical analysis. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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attenuated in HoipDhep livers at this stage (Fig. 3B).
Hence, increased cell death appeared to be the ﬁrst
pathological event in HOIP-deﬁcient livers.
To better characterize the type of cell death observed
in the absence of HOIP from LPCs, we performed ter-
minal deoxynucleotidyl transferase–mediated deoxyuri-
dine triphosphate nick-end labeling (TUNEL) and
cleaved caspase-3 (CC3) stainings. Both TUNEL1 and
apoptotic CC31 cells were signiﬁcantly increased at 2, 4,
and 8 weeks of age in HoipDhep livers (Fig. 3C; Support-
ing Fig. S4B). Notably, the number of dead cells was
moderately elevated already during the ﬁrst week of life
in HoipDhep livers (Fig. 3C). The numbers of both
TUNEL1 and CC31 cells per area peaked at 2 weeks of
age, thereby preceding the peak of liver leukocyte count
and serum ALT levels by 2 weeks (Figs. 2A and 3A). To
evaluate whether caspase-3 activation could be a conse-
quence of caspase-8 cleavage, lysates from Hoipﬂox and
HoipDhep livers were analyzed by western blotting.
Caspase-8 cleavage was indeed elevated in the livers of
HoipDhep mice at 4 weeks of age (Supporting Fig. S4C).
In accord, primary hepatocytes from HoipDhep mice dis-
played activation of caspase-3 as well as caspase-8 cleav-
age in their lysates (Fig. 3D). No obvious differences in
the levels of any of the proapoptotic and antiapoptotic
proteins evaluated in HOIP-deﬁcient hepatocytes was
observed (Supporting Fig. S4D). Of note, we detected
increased phosphorylation of IjBa and c-Jun N-terminal
kinase (JNK), accompanied by a reduction in the levels of
IjBa in HoipDhep livers, which is likely a consequence of
the ongoing inﬂammation in these livers (Supporting
Fig. S4E). Taken together, HoipDhep livers exhibit
increased hepatocyte death, characterized by prominent
activation of caspase-8 and caspase-3 as well as TUNEL
positivity. Hence, mice with HOIP deﬁciency in the liver
suffer from hepatocyte apoptosis which precedes the
emergence of hepatitis.
HOIP-DEFICIENT HEPATOCYTES
ARE MORE SENSITIVE TO
APOPTOSIS INDUCTION BUT
LESS CAPABLE OF NF-jB
ACTIVATION BY VARIOUS
IMMUNE RECEPTOR STIMULI
It has been established that LUBAC deﬁciency
leads to aberrant TNFR1 and other immune receptor
signaling output,(17,19-21,23) which could account for
the increased liver cell death in HoipDhep mice. Indeed,
HOIP-deﬁcient primary hepatocytes were more
sensitive to cell death induction by TNF, CD95 ligand
(CD95L/FasL), and polyinosinic:polycytidylic acid
(poly(I:C)) but not TNF-related apoptosis-inducing
ligand (TRAIL) (Fig. 4A). We also assessed whether
HOIP-deﬁcient hepatocytes have a defect in gene acti-
vation. HOIP-deﬁcient primary hepatocytes showed
substantially reduced phosphorylation and subsequent
degradation of IjBa upon TNF stimulation and a
slight reduction in JNK activation (Fig. 4B). Extracel-
lular signal–regulated kinase (ERK) activation was not
observed upon TNF stimulation, yet HOIP-deﬁcient
cells had a higher basal level of phosphorylated extra-
cellular signal–regulated kinase (Fig. 4B). In addition,
phosphorylation of IjBa upon stimulation by CD95L
or poly(I:C) was decreased in HOIP-deﬁcient hepato-
cytes, but phosphorylation of JNK was unaltered (Fig.
4C,D). These results illustrate that HOIP deﬁciency
mainly dampens NF-jB signaling in hepatocytes
induced by multiple immune receptor stimuli. Notably,
the basal level of phosphorylated IjBa was also
reduced in HOIP-deﬁcient cells (Fig. 4B-D, ﬁrst lanes
of Hoipﬂox and HoipDhep cells), implying that HOIP
contributes to the induction of physiological levels of
NF-jB activation in hepatocytes in response to various
stimuli, as reported for other cell types.(19,20,25,31)
HOIP SUPPRESSES
FORMATION OF THE CELL
DEATH–TRIGGERING
SIGNALING COMPLEX
INDEPENDENTLY
OF ITS GENE-ACTIVATING
FUNCTION
Because impaired gene activation can result in
increased susceptibility to cell death, we next evaluated
whether or not the increased sensitivity of HOIP-
deﬁcient hepatocytes to TNF-induced cell death is a
consequence of impaired NF-jB–induced gene activa-
tion. To do so, we treated HOIP-proﬁcient and HOIP-
deﬁcient cells with TNF in combination with cyclohexi-
mide (CHX). HoipDhep hepatocytes were still more sus-
ceptible to TNF/CHX-induced death than control cells
(Fig. 5A), demonstrating that HOIP can protect hepa-
tocytes from TNF-induced cell death independently of
its role in gene activation. We previously showed that
stimulation of HOIP-deﬁcient mouse embryonic ﬁbro-
blasts results in aberrant formation of TNFR1 complex
II, which contains FADD–caspase-8–RIPK1 and is
responsible for the increased death observed in these
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cells.(20) Strikingly, HOIP-deﬁcient hepatocytes dis-
played robust formation of such a death-triggering com-
plex containing FADD, caspase-8 (full-length and
cleaved), RIPK1, and cellular FLICE-like inhibitory
protein long isoform (c-FLIPL), while its formation was
limited in HOIP-proﬁcient primary hepatocytes (Fig.
5B, compare the ﬁrst and second lanes). Intriguingly,
this complex was readily formed in the absence of any
exogenous stimulation. Hence, this evidence implies that
HOIP-deﬁcient hepatocytes die as a consequence of the
aberrant formation of this complex and caspase-
8 activation.
In sharp contrast to the marked increase in the for-
mation of this complex by HOIP deﬁciency,
abrogation of gene translation by treatment with the
inhibitor CHX did not elevate formation of this com-
plex in HOIP-proﬁcient hepatocytes (Fig. 5B, com-
pare the ﬁrst and fourth lanes). This result
demonstrates that failure of gene activation, including
that of NF-jB target genes, does not account for the
aberrant assembly of the FADD-associated signaling
complex that occurs in the absence of HOIP. These
results imply that LUBAC exerts a suppressive func-
tion in hepatocytes toward formation of the FADD–
RIPK1–caspase-8–c-FLIPL–containing complex and
caspase-8 activation independently of its gene-
activating capacity, which results in promoting protu-
morigenic events ensuing from cell death (Fig. 5C).
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FIG. 4. HOIP is required for suppression of cell death and optimal NF-jB activation in hepatocytes in response to various immune
receptor stimuli. (A) Cell viability assay of primary hepatocytes from Hoipﬂox and HoipDhep mice with the indicated treatments. Cells
were treated with 1 lg/mL of TRAIL, CD95L-Fc, and poly(I:C) for 24 hours (n5 3 each). Unpaired two-tailed t test was employed
for statistical analysis. (B-D) Primary hepatocytes were stimulated with 10 ng/mL TNF (B), 1 lg/mL poly(I:C) (C), or 0.5 lg/mL
CD95L-Fc (D) for the indicated times; and hepatocyte lysates were immunoblotted for the indicated proteins. Abbreviations:
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; pERK, phosphorylated ERK; pJNK, phosphorylated JNK.
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TNFR1 DELETION IS NOT
SUFFICIENT TO PREVENT
THE DEATH OF HOIP-
DEFICIENT HEPATOCYTES
HOIP-deﬁcient hepatocytes are more sensitive to
TNF-induced cell death (Fig. 4A). In addition,
previous work has demonstrated that the aberrant cell
death observed in SHARPIN-deﬁcient and HOIP-
deﬁcient mice is rescued by genetic ablation of
TNFR1.(19-21,23) We therefore hypothesized that
exacerbated cell death and inﬂammation in HOIP-
deﬁcient livers was also mediated by TNFR1 signaling.
Unexpectedly, however, when we crossed HoipDhep
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FIG. 5. HOIP restrains formation of the cell death–inducing FADD–RIPK1–caspase-8–c-FLIPL–containing complex in hepatocytes,
independently of its gene-activating function. (A) Cell viability assay of primary hepatocytes isolated from Hoipﬂox and HoipDhep mice,
treated with 1 lg/mL TNF for 24 hours in the presence or absence of 1 lg/mL CHX. Unpaired two-tailed t test was employed for
statistical analysis. (B) Immunoprecipitation of the FADD-associated complex in z-VAD-fmk(zVAD)–treated (24 hours) primary
hepatocytes from Hoipﬂox (F) and HoipDhep (D) mice in the absence or presence of 1 lg/mL CHX. Asterisks indicate unspeciﬁc bands.
(C) Schematic representation of the role of LUBAC in HOIP-proﬁcient and HOIP-deﬁcient hepatocytes. Abbreviations: GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; IP, immunoprecipitation.
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mice with mice constitutively devoid of TNFR1
(Tnfr1KO) mice, the damage in the resulting Tnfr1KO
HoipDhep livers was similar to that in HoipDhep livers as
assessed by serum ALT values and histological analysis
(Fig. 6A,B). Furthermore, codeletion of TNFR1 did not
reduce the numbers of TUNEL1 and CC31 cells in
HOIP-deﬁcient livers (Fig. 6C). In line with these
results, activation of caspase-8 and caspase-3 was equiva-
lent in Tnfr1KO HoipDhep and HoipDhep hepatocytes (Fig.
6D) and TNFR1 ablation did not prevent formation of
the FADD–RIPK1–caspase-8–c-FLIPL–containing
complex in HOIP-deﬁcient hepatocytes (Fig. 6E).
As HOIP-deﬁcient hepatocytes were highly sensitive
to CD95L (Fig. 4A), we next sought to determine
whether stimulation of CD95 could be responsible for
increased cell death in Tnfr1KO HoipDhep livers.We,
therefore, crossed Tnfr1KO HoipDhep mice with Cd95-
DDﬂox mice to delete the DD of CD95 in LPCs. We
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FIG. 6. Hepatocyte apoptosis in HOIP-deﬁcient livers is unaffected by genetic ablation of TNFR1. (A) Levels of serum ALT in
Hoipﬂox, HoipDhep, and Tnfr1KO HoipDhep mice at the indicated ages. (B) Representative pictures of hematoxylin and eosin sections of
the livers of Tnfr1KO HoipDhep mice at 2 and 4 weeks of age. Arrowheads indicate apoptotic bodies. (C) Quantiﬁcation of CC31 and
TUNEL1 cells per area of the livers of Hoipﬂox, HoipDhep, and Tnfr1KO HoipDhep mice at 2 weeks of age. (D) Lysates of primary hepa-
tocytes from Hoipﬂox (F), HoipDhep (D), and Tnfr1KO HoipDhep (TD) mice at 8 weeks of age were immunoblotted for CC8 and CC3.
(E) Immunoprecipitation of the FADD-associated complex in zVAD-treated (24 hours) primary hepatocytes from Hoipﬂox (F),
HoipDhep (D), and Tnfr1KO HoipDhep (TD) mice. Asterisks indicate unspeciﬁc bands. Unpaired two-tailed t test was employed for statis-
tical analysis. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IP, immunoprecipitation.
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conﬁrmed that hepatocytes from Cd95-DDDhep Tnfr1KO
HoipDhep mice failed to activate caspases upon CD95L
stimulation (Supporting Fig. S5A). Despite the func-
tionally complete deletion of both TNFR1 and the DD
of CD95, Cd95-DDDhepTnfr1KO HoipDhep mice had sig-
niﬁcantly higher ALT in the serum (Supporting Fig.
S5B). In accordance, hepatocytes isolated from these
animals contain the FADD-associated caspase-8–acti-
vating complex to a similar extent as those obtained
fromHoipDhep mice (Supporting Fig. S5C). Thus, ablat-
ing the capacity of CD95 to induce cell death, in addi-
tion to fully ablating TNFR1, does not prevent the
increase in aberrant cell death which characterizes
HOIP-deﬁcient livers.
TNFR1 MEDIATES HEPATITIS
AND TUMORIGENESIS UPON
LOSS OF HOIP IN THE LIVER
We next evaluated the effect of TNFR1 ablation on
hepatitis in HoipDhep mice. Remarkably, even though
cell death was unaffected in Tnfr1KO HoipDhep livers
(Fig. 6), the number of leukocytes present in these livers
was signiﬁcantly lower than in HoipDhep livers (Fig. 7A).
The transcript levels of Tnf and Ccl3 were also markedly
decreased in Tnfr1KO HoipDhep livers (Fig. 7B). Further-
more, the numbers of hepatic myeloid cells as well as
CD81 T cells and B cells were diminished by TNFR1
ablation (Fig. 7C). In accordance with attenuated
inﬂammation, DNA damage in HoipDhep livers was sig-
niﬁcantly alleviated by deletion of TNFR1, as con-
ﬁrmed by cH2AX staining (Fig. 7D). To evaluate the
effect of TNFR1 deletion in tumorigenesis driven by
HOIP deﬁciency, we also analyzed livers of Tnfr1KO
HoipDhep mice at 18 months of age. The incidence of
macroscopic nodules was considerably reduced in these
mice compared to HoipDhep mice. Moreover, Tnfr1KO
HoipDhep mice displayed decreased lesion numbers and
the lesions that did arise were considerably smaller in
size than in HoipDhep mice (Fig. 7E,F). Collectively,
these results demonstrate that TNFR1 signaling con-
tributes to HOIP deﬁciency–mediated liver inﬂamma-
tion and carcinogenesis even though exacerbated
hepatocyte death, likely the event that triggers these
consequences, still occurs in the absence of TNFR1.
Discussion
Here, we evaluated the impact of LUBAC deﬁciency
on liver homeostasis by genetically ablating HOIP, the
catalytically active component of LUBAC, in mouse
LPCs. LUBAC deﬁciency in LPCs results in hepatocyte
apoptosis, followed by inﬂammation in the liver within
the ﬁrst month of life and tumorigenesis at 18 months of
age. Intriguingly, cell death regulation by LUBAC in
hepatocytes is independent of its function in gene activa-
tion and, importantly, requires neither TNFR1 nor the
DD of CD95 in vivo. Yet, TNFR1 contributes to the
inﬂammatory processes that are likely triggered by the
aberrant death of HOIP-deﬁcient hepatocytes and which
eventually results in liver carcinogenesis.
The ﬁrst aberration we detected in HOIP-deleted
livers was an increased level of apoptosis at postnatal
day 7 before inﬂammation became noticeable. Patients
suffering from chronic hepatitis, including viral hepati-
tis and nonalcoholic steatohepatitis, display hepatocyte
death.(32) In addition, apoptosis can be a potent driver
of inﬂammation and liver tumorigenesis.(11,33) Apo-
ptotic cells elicit activation of the immune system and
production of mediators of inﬂammation, which can
also activate the regenerative process of hepatocytes. In
fact, cytokines and growth factors involved in tissue
regeneration are linked to tumor promotion.(34,35) Fur-
thermore, it is possible that the DNA-damaging envi-
ronment in HOIP-deﬁcient livers is promoted by
impaired NF-jB activation in addition to cell death,
which was illustrated in the studies using LPC-speciﬁc
IKKb knockout mice.(8,34) We therefore postulate that
HOIP deletion initially affects liver homeostasis by
promoting hepatocyte apoptosis and that this, through
facilitating liver inﬂammation, regeneration, and DNA
damage, creates a protumorigenic environment which
enables the formation of HCC.
Alb-Cre–mediated target gene deletion occurs gradu-
ally from late gestation to approximately 6 weeks of
age.(24) Because HOIP deletion in hepatocytes of
HoipDhep mice is efﬁciently executed at 8-10 weeks of
age, HOIP deletion should be completed by this stage
and no new HOIP-depleted cell are generated. Loss of
HOIP causes hepatocyte death, yet a fraction of HOIP-
deﬁcient cells appear to be able to survive. As the num-
ber of HOIP-deleted cells approaches a plateau, the
number of newly HOIP-deleted cells declines, which
would provide a decreased source of apoptotic cells,
hence explaining the kinetics of cell death observed in
HoipDhep mice. Remarkably, even though cell death and
inﬂammation are resolved during adulthood in HoipDhep
mice, the events occurring at early stages of life are sufﬁ-
cient to cause liver tumorigenesis late in life.
Unexpectedly, unlike our previous observations in
SHARPIN-deﬁcient cpdm mice(19,21,23) and HOIP-
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FIG. 7. TNFR1 mediates inﬂammation and promotes carcinogenesis in HOIP-deﬁcient livers. (A) Count of hepatic CD451 cells
per gram of liver in Hoipﬂox, HoipDhep, and Tnfr1KO HoipDhep mice at 4 weeks of age. (B) Relative quantiﬁcation of the transcript levels
of Tnf and Ccl3 in the liver of Hoipﬂox, HoipDhep, and Tnfr1KO HoipDhep mice at 4 weeks of age. Levels of transcripts were normalized
to those of Hoipﬂox livers. (C) Liver cells from HoipDhep and Tnfr1KO HoipDhep mice at 4 weeks were stained, and the numbers of
hepatic immune subpopulations were quantiﬁed by ﬂow cytometry. (D) Quantiﬁcation of cH2AX1 cells per ﬁeld of the liver of Hoip-
ﬂox, HoipDhep, and Tnfr1KO HoipDhep mice at 4 weeks of age. Unpaired two-tailed t test was employed for statistical analysis (A-D). (E)
Representative pictures of livers of HoipDhep, Tnfr1KO HoipDhep, and Tnfr1KO Hoipﬂox mice at 18 months of age (left panels). (F) Com-
parison between HoipDhep, Tnfr1KO HoipDhep, and Tnfr1KO Hoipﬂox mice on the incidence of macroscopic nodules (diameter >2 mm)
(upper graph), maximal lesion size (middle graph), and lesion number (lower graph). Abbreviations: Bc, B2201 cells; CD4 Tc, CD31
CD41 cells; CD8 Tc, CD31 CD81 cells; Gr, Ly6G1 cells; Mo/MF, F4/801 cells; NK, CD32 NK1.11 natural killer cells; NKT,
CD31 NK1.11 natural killer T cells.
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deﬁcient embryos,(20) LUBAC deﬁciency–mediated
hepatocyte apoptosis does not require TNFR1. Yet
intriguingly, the subsequent enhanced leukocyte recruit-
ment observed in mice proﬁcient for TNFR1 is reverted
to normal levels by systemic ablation of TNFR1 in mice
with HOIP-deﬁcient livers. This evidence indicates that,
while the cell death does not require TNFR1, this recep-
tor contributes to the ensuing inﬂammation. Thus,
TNFR1 signaling from nonparenchymal liver cells,
including from immune, hepatic stellate, and endothelial
cells, might be involved in the development of hepatitis
in mice with HOIP-deﬁcient livers. Furthermore, in line
with decreased inﬂammation, TNFR1 ablation signiﬁ-
cantly reduced cH2AX1 cells in HOIP-deﬁcient livers.
Apart from inﬂammation, caspase activation observed in
HOIP-deﬁcient hepatocytes could also be responsible
for the induction of DNA damage by resulting in DNA
fragmentation. In fact, DNA damage was not complete-
ly inhibited despite the apparent absence of inﬂamma-
tion by TNFR1 deﬁciency. These results suggest that
DNA damage in the liver may be induced as a conse-
quence of both TNFR1-independent caspase activation
and TNFR1-dependent inﬂammation. Previous studies
revealed the tumor-promoting role of TNF in
carcinogen-induced liver cancer.(35) In accord, TNFR1
ablation prevented tumorigenesis triggered by HOIP
deﬁciency, presumably by inhibiting inﬂammation and
subsequent DNA damage.
HOIP-deﬁcient hepatocytes are sensitized to death
induction by triggering of CD95 and toll-like receptor
3 but not TRAIL. While this result suggests CD95
and toll-like receptor 3 as possible candidate receptors
for mediating hepatocyte death in HoipDhep mice, the
liver cell death observed in HoipDhep mice could be
mediated by entirely other systems capable of inducing
cell death and for which a role of LUBAC has not yet
been described. In fact, in addition to CD95L and
poly(I:C), TNF was capable of enhanced killing of
HOIP-deﬁcient compared to HOIP-proﬁcient hepa-
tocytes, yet ablation of TNFR1 alone or the combined
deletion of TNFR1 and the DD of CD95 was not suf-
ﬁcient to prevent cell death in the livers of these mice.
Of note, inﬂammation driven by NF-jB essential
modulator deﬁciency in the liver parenchyma is not
ameliorated by concomitant LPC-speciﬁc abrogation
of TNFR1, TRAIL receptor, and/or the DD of
CD95.(36) It is therefore tempting to speculate that a
yet unidentiﬁed immune receptor, or indeed a com-
bination of multiple immune receptors, might be
responsible for hepatocyte cell death and the ensuing
inﬂammation upon HOIP deﬁciency in vivo.
Alternatively, aberrant cell death could be a conse-
quence of spontaneous formation of the killing complex
in the absence of an exogenous stimulus. Indeed, loss of
cellular inhibitor of apoptosis proteins by Smac mimetic
treatment alone results in spontaneous formation of a
FADD–RIPK1–caspase-8–containing complex, termed
the “ripoptosome,”(37,38) which is reminiscent of the sig-
naling complex present in HOIP-deﬁcient hepatocytes.
The ripoptosome is assembled independently of auto-
crine TNF, TRAIL, and CD95L.(37,38) Additional
recent studies illustrated the crucial role of RIPK1 and
its kinase activity in the formation of the FADD–
RIPK1–caspase-8 apoptotic signaling complex.(13,39,40)
In particular, aberrant cell death causative for the
inﬂammatory phenotype that characterizes cpdm mice is
completely prevented by genetic inactivation of RIPK1’s
kinase activity.(41) It would therefore be interesting to
interrogate the role of the kinase activity of RIPK1 in
aberrant death complex formation and apoptosis driven
by HOIP deﬁciency in hepatocytes.
HOIP deletion in the liver parenchyma results in
cancer formation with overexpression of mitotic genes.
A class of human HCC with robust up-regulation of
mitosis and cell cycle regulators was identiﬁed by Thor-
geirsson and colleagues, who termed this subclass A and
reported a strong correlation with poor prognosis of
patients with HCC.(28) Moreover, according to the clas-
siﬁcation of human HCC by Boyault et al. into sub-
groups G1-G6, this signature resembles that of the G3
subgroup of hepatitis B virus–free HCC with highly
overexpressed cell cycle regulatory genes.(27) In addition,
these nodules displayed up-regulation of fetal liver genes
as observed in the G1 subgroup. Both the G1 and G3
subgroups belong to the meta-group G1-G3, which is
linked to higher genomic instability and which corre-
sponds to subclass A. In summary, the tumor nodules
found in HoipDhep mice appear to recapitulate the proﬁle
of hepatitis B virus–negative human HCC with chro-
mosomal instability and a more unfavorable outcome.
The pathology of HoipDhep livers does not mirror the
currently most common process of liver carcinogenesis,
arising as a consequence of cirrhosis. However, there is
an increasing trend of patients suffering from HCC,
particularly in the Western world, associated with obe-
sity and metabolic syndrome but without prior history
of cirrhosis.(42) In our mouse model, tumor-bearing
HOIP-deﬁcient livers exhibited steatotic features,
which may indicate some metabolic alterations in hep-
atocytes. Therefore, HoipDhep livers could imitate the
progression of nonalcoholic fatty liver disease to HCC,
bypassing a cirrhotic condition. It would therefore be
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tempting to speculate that HOIP deﬁciency in the liver
could mimic the conditions in nonalcoholic fatty liver
disease patients and could possibly serve as a model for
its etiology. The pathologies found in HoipDhep livers
appear to be driven by aberrant cell death, which is
often seen in hepatitis patients. It is therefore possible
to envisage that blockade of cell death may be of thera-
peutic beneﬁt for patients suffering liver complications
including nonalcoholic fatty liver disease. Indeed, the
caspase inhibitor emricasan (IDN-6556) has been
shown to alleviate liver damage in human patients,(43)
and a clinical trial testing its effects on nonalcoholic
steatohepatitis and liver ﬁbrosis is currently under way
(ClinicalTrials.gov identiﬁer NCT02686762).
In conclusion, LUBAC is a previously unidentiﬁed
tumor suppressor inhibiting hepatocyte apoptosis at
postnatal stages that does not require TNFR1. In the
absence of LUBAC, a tumor-conducive inﬂammatory
environment emerges in these livers which have suffered
from hepatocyte apoptosis followed by compensatory
proliferation. The development of this environment
involves hepatitis and DNA damage, which, in turn, are
dependent on TNFR1. These results identify LUBAC
as a crucial factor ensuring hepatocyte survival and as a
suppressor of hepatitis and hepatocarcinogenesis.
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